New hope for recurrent ovarian cancer? early trial combines novel PARP inhibitor with chemo

NCT ID NCT06930755

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if the combination shrinks tumors. It is for patients who have tried up to 5 prior therapies and have no other standard options left.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian serous adenocarcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • OSF Saint Francis Medical Center

    RECRUITING

    Peoria, Illinois, 61637, United States

  • Penn Medicine - Perelman Center for Advanced Medicine

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Washington University School of Medicine in St. Louis

    RECRUITING

    St Louis, Missouri, 63130, United States